why choose us

First received: July 15, 2022

Clinical Trial: Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Furmonertinib

Study Type: INTERVENTIONAL


Official Title: Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Prospective, Open-label, Phase II Trial?iFORCE?

Brief Summary: This study is a single-arm, open-label, prospective phase II trial.The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Read more